Modulateur du CFTR

Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor

Etude : Ivacaftor, Lumacaftor
Type d'étude : Modulateur du CFTR
Titre : A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR MutationA
Phase : 3
Promoteurs :

Age : 6 Years and Older
Lien internet : https://clinicaltrials.gov/ct2/show/NCT02544451

Study of GLPG1837 in Subjects With Cystic Fibrosis (G551D Mutation) (SAPHIRA1)

Etude : GLPG1837
Type d'étude : Modulateur du CFTR
Titre : A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 Administered Orally Once-Daily for 48 Weeks in Adult Patients With Cystic Fibrosis
Phase : 2a
Promoteurs :

Age : 18 Years and Older
Lien internet : https://clinicaltrials.gov/ct2/show/NCT02707562

A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis Who Have an F508del-CFTR Mutation

Etude : VX-661 / Ivacaftor
Type d'étude : Modulateur du CFTR
Titre : A Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
Phase : 3
Promoteurs :

Age : 12 Years and Older
Lien internet : https://clinicaltrials.gov/ct2/show/NCT02565914

A Phase 3 Study of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor

Etude : VX-661/ ivacaftor
Type d'étude : Modulateur du CFTR
Titre : A Phase 3, Randomized, Double-Blind, Ivacaftor-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation and a Second CFTR Allele With a Gating Defect That Is Clinically Demonstrated to be Ivacaftor Responsive
Phase : 3
Promoteurs :
Belgium : Leuven
Italy : Milan, Rome
UK: Belfast, Birmingham, Leeds, London
Age : 12 Years and Older
Lien internet : https://clinicaltrials.gov/ct2/show/NCT02412111